20-23 JUL 2008
SPONSOR & EVENT :: AACR Translational Cancer Medicine
Monterey, CA | Hyatt Regency Monterey

POSTER SESSION A:: Drug Development/New Technologies
A survey of MAPK pathway signature activation in tumors and association with sensitivity to targeted therapies
Dr. Daniel R. Rhodes | Monday, Jul 21, 2008, 6:00 PM | Regency Grand Ballroom I-III

Show Web Site

12-16 APR 2008
EVENT :: AACR Annual Meeting
San Diego, CA | SD Convention Center

SYMPOSIUM :: Molecular and Clinical Insights into Cancers Affecting Under-represented Populations
Meta-analysis of outlier profiles in breast cancer identifies AGTR1 over-expression and copy number gain as an opportunity for targeted therapy
Dr. Daniel R. Rhodes | Tuesday, Apr 15, 2008, 4:15 PM | Room 6C

Late-Breaking Poster Session :: Cellular and Molecular Biology 5
#LB-283 Meta-analysis of outlier expression profiles in breast cancer identifies AGTR1 overexpression as an opportunity for targeted therapy
Dr. Daniel R. Rhodes | Tuesday, Apr 15, 2008, 1:00-5:00 PM | Exhibit Hall B-F, Section 19, Board 11

Poster Session :: Molecular Determinants of Tumor Susceptibility and Progression
#4567 TMPRSS2-ERG fusion prostate cancer is a molecularly distinct estrogen-sensitive subclass of aggressive prostate cancer
Dr. Daniel R. Rhodes | Tuesday, Apr 15, 2008, 1:00-5:00 PM | Exhibit Hall B-F, Section 14, Board 22

Show Web Site

7-9 APR 2008
EVENT :: BIO-Europe
Madrid, Spain

INTERACTIVE WORKSHOP :: Why should BD care about Translational Medicine?

Show Web Site

25-28 MAR 2008
EVENT :: Molecular Medicine Tri-Conference
San Francisco, CA | Booth #309

POSTER :: Investigating biological associations of Dasatinib drug sensitivity using Molecular Concepts Analysis

Show Web Site

4-5 JUN 2007
PARTNER EVENT :: San Francisco, CA at the Hyatt Hotel, Fisherman's Wharf
Ingenuity Systems U.S. User Group Meeting and IPA Workshop
Ingenuity Systems

25 JUN 2008
WEBINAR :: Meta-COPA: The SPINK1 Case Study

Recently, Oncomine™ played a central role in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer (Cancer Cell, Volume 13 Issue 6: June 2008). Dr. Dan Rhodes and his colleagues at the University of Michigan expanded on the Cancer Outlier Profile Analysis (COPA) work they started with the ETS-family gene fusions in prostate cancer by performing a meta-analysis of the outlier results — Meta-COPA — to identify SPINK1 as their gene of interest. In this webinar Dr. Rhodes will use the SPINK1 discovery as a case study to walk through the process used to identify the gene of interest through Meta-COPA analysis and then further verify the hypothesis with Oncomine. The COPA analysis is currently available in Oncomine v3.6. Meta-COPA is slated to be a standard feature in v4.0 to be released this fall.

Download slides (PDF 1.49 MB) | Open Flash Movie

28 MAY 2008
WEBINAR :: Target Discovery in Oncomine: Integrating -omics data

Oncomine contains a wealth of gene expression data and analysis from tumors and cell lines. While gene expression analysis represents an important component of drug target discovery and validation, it alone may not be sufficient to identify optimal targets. In this webinar, Dr. Dan Rhodes will present Oncomine-based target discovery strategies that integrate gene expression data with additional genomics data types and resources including DNA copy number data and the COSMIC somatic mutation database. We will also explore analyses of gene expression data filtered by functional genomics shRNA data.

Download slides (PDF 1.41 MB) | Open Flash Movie

19 MAR 2008
WEBINAR :: MAPK Pathway Signatures in Oncomine

Our newest commitment the academic community is this webinar series aimed at demonstrating the value of assembling this wide range of academic data within a single, comprehensive, standardized database.

Pioneering work by Nevins and colleagues demonstrated that microarray-based pathway activation signatures can be used to predict pathway activity in human tumors and suggest strategies for tailoring targeted therapies. In this webinar, we utilize the Oncomine Concepts Map to analyze recently published pathway activation signatures for EGFR, ERBB2, B-Raf and Mek. We demonstrate that pathway activation signatures are associated with drug sensitivity as well as specific tumor sub-populations, suggesting new avenues for genomics-based drug development.

Download slides (PDF) | Download WMV (17.3 MB) | Download Paper (PDF)

28 JUN 2007
WEBINAR :: Identifying relationships between disease, pathways, regulation and drugs using Oncomine Concepts Map
Download WMV (22.3 MB)

31 MAY 2007
WEBINAR :: Accelerating discovery by integrating the Oncomine cancer profiling platform with Ingenuity Pathways Analysis